The Need for New Anti-Hepatitis C Virus Therapeutic Strategies Targeting the cellular micro-ribonucleic acids?

Infection with the hepatitis c virus (hcv) is a worldwide problem. patients with chronic hcv infection who are non-responders to standard therapy represent a growing population within the hcv epidemic. novel, more efficient and tolerable therapies are urgently needed. this review discusses the recent results showing that targeting mir-122, a micro-ribonucleic acid (microrna) that enhances hcv replication, is a new anti-hcv therapy with a high barrier to resistance.